However, what can be drawn from this study is that this 6-miRNA signature can also work in serum in the CRC screening setting and that, more importantly, it is the first time that this circulating 6-miRNA signature is compared with another non-invasive biomarker such as the f(Hb) showing its superiority for precancerous lesions, and combined with it to improve overall diagnostic performances. Here, GSTM1 is linked to colorectal carcinoma.